Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 3/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818485 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HPGDHTTSMN1; SMN2ERN1 | |
| SCHEMBL812635 | 0.85 | ALDH1A1 (0.77) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL30920025 | 0.85 | ALDH1A1 (0.77) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL5434859 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDHTTSMN1; SMN2ERN1 | |
| SCHEMBL29923063 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HPGDHTTSMN1; SMN2ERN1 | |
| SCHEMBL5456528 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HPGDHTTSMN1; SMN2ERN1 | |
| SCHEMBL5724553 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HPGDHTTSMN1; SMN2ERN1 | |
| SCHEMBL16958262 | 0.83 | HTR1B (0.40) | ALDH1A1HPGDHTTSMN1; SMN2CYP2A6 | |
| SCHEMBL16955133 | 0.83 | HTR1B (0.40) | ALDH1A1HPGDHTTSMN1; SMN2ERN1 | |
| SCHEMBL12610716 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HPGDHTTSMN1; SMN2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
| EP-0593513-B1 | TRYPTAMINE ANALOGUES, THEIR SYNTHESIS AND THEIR USE AS 5-HT1-LIKE RECEPTORS OR 5-HT2 RECEPTOR AGONISTES | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | EP | disclosed |
| US-5571833-A | TREATMENT OF MIGRAINE, PORTAL HYPERTENSION | SMITHKLINE BEECHAM PLC (GB) | 1996-11-05 | — | — | US | disclosed |
| EP-0593513-A1 | TRYPTAMINE ANALOGUES, THEIR SYNTHESIS AND THEIR USE AS 5-HT1-LIKE RECEPTORS OR 5-HT2 RECEPTOR AGONISTES | SMITHKLINE BEECHAM PLC (GB) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993000333-A1 | TRYPTAMINE ANALOGUES, THEIR SYNTHESIS AND THEIR USE AS 5-HT1-LIKE OR 5-HT2 RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | TBCA, TBCB, BTD | ALDH1A1 4409/4885HPGD 4390/4885HTT 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.